Project Grant R35HL176438
Award Date
8/1/25
Completion Date
4/30/32
Dollars Obligated
$1.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $129,137 to the University of California, Los Angeles (UCLA) to examine the role of long noncoding RNAs (lncRNAs) in hepatic lipid metabolism and their potential implications for cardiovascular and metabolic diseases. The primary objectives are to (1) investigate the influence and mechanism of the lncRNA XTENDR on hepatic lipid homeostasis and sex-specific hepatic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,352,138 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Rector & Visitors of the University of Virginia. The grant aims to model and experimentally validate cell-specific signaling networks involving the low-density lipoprotein receptor-related protein 1 (LRP1) in acute myocardial infarction (AMI). The research will focus on understanding how early cardiomyocyte LRP1 signaling enhances cell...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $299,504 Project Grant to Imetabolic Biopharma Corp on Sep 15, 2024. The grant supports the development of a novel therapeutic approach to clear small dense low-density lipoprotein (sdLDL) from circulation. The research aims to reengineer an APOC-III antagonist, IMBP-001, to include bioactive APOE mimetic peptides. This dual-domain therapeutic candidate can bind to...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $603,632.00 to The Johns Hopkins University to conduct research on the role of the PLA2G12B protein in the assembly and metabolism of triglyceride-rich apolipoprotein B-containing lipoproteins. The research aims to elucidate the mechanisms by which PLA2G12B channels triglycerides into...
This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) totaling $1,602,792 provides funding to the University of North Carolina at Chapel Hill to investigate the phenotypic consequences of lipoprotein(a) in diverse global populations. The project aims to address key research gaps by assembling the largest and most ancestrally diverse consortium with validated lipoprotein(a) measures and genetic data. This will enable...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $171,450.00 to investigate the biological mechanisms linking excess body fat (adiposity) and elevated blood lipid levels, and their combined impact on cardiovascular disease risk. The research, led by Dr. Dron, a computational geneticist, aims to: 1) measure how adiposity interacts with genetic variants to influence lipid levels, 2)...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The award, effective July 15, 2024 through June 30, 2028, will support research to: (1) identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol...